AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03876639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of emulsion
Description: Daily application of the assigned formulation on the non-dominant volar forearm for 4 weeks
Study NCT04640402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen
Description: 60-85 years group, two doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
Study NCT04640402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen
Description: 60-85 years group, three doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
Study NCT04640402 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose placebo (18-59 years) & Two dose regimen
Description: 18-59 years group, two doses of placebo(0.5ml) at the schedule of day 0, 21.
Study NCT04640402 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose placebo (18-59 years) & Three dose regimen
Description: 18-59 years group, three doses of placebo(0.5ml) at the schedule of day 0, 14, 28.
Study NCT04640402 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: High-dose placebo (18-59 years) & Two dose regimen
Description: 18-59 years group, two doses of placebo(1.0ml) at the schedule of day 0, 21.
Study NCT04640402 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: High-dose placebo (18-59 years) & Three dose regimen
Description: 18-59 years group, three doses of placebo(1.0ml) at the schedule of day 0, 14, 28.
Study NCT04640402 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose placebo (60-85 years) & Two dose regimen
Description: 60-85 years group, two doses of placebo(0.5ml) at the schedule of day 0, 21.
Study NCT04640402 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose placebo (60-85 years) & Three dose regimen
Description: 60-85 years group, three doses of placebo(0.5ml) at the schedule of day 0, 14, 28.
Study NCT04640402 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: High-dose placebo (60-85 years) & Two dose regimen
Description: 60-85 years group, two doses of placebo(1.0ml) at the schedule of day 0, 21.
Study NCT03876639 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of physiological skin parameters
Description: Weekly measurement of physiological skin parameters using confocal Raman spectroscopy, Corneometer® CM 825, Sebumeter®, Skin-pH-Meter®, AquaFlux® and Epsilon®
Study NCT03876639 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tape stripping
Description: Removal of 40 adhesive strips after application of a model drug-loaded emulsion and determination of the transepidermal water loss
Study NCT03992222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical exercise programs PEP targeted on appropriate muscle strengthening devices allows
Description: administration of a Physical exercise program for 24 weeks.The participants will be followed at the 24 and 52nd weeks.
Study NCT03769025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suboxone Remote Observed Dosing
Description: The remote observed dosing group will use the provided smartphone to video record themselves taking their Suboxone dose each day
Study NCT03769025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suboxone Attention Control
Description: Attention control group will send a text message daily confirming that they have taken their Suboxone dose
Study NCT00640562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Extended Release
Description: Uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
Study NCT00640562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.
Study NCT01400087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cap-attached Colonoscopy Versus Regular Colonoscopy
Description: Trainees were divided into two group; Cap-attached Colonoscopy group or Regular Colonoscopy group. Trainees allocated to the former group undergo colonoscopy with cap for all cases, the latter without cap.
Study NCT01400087 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cap-attached Colonoscopy Versus Regular Colonoscopy
Description: Trainees were divided into two group; Cap-attached Colonoscopy group or Regular Colonoscopy group. Trainees allocated to the former group undergo colonoscopy with cap for all cases, the latter without cap.
Study NCT01384591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Study NCT01384591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Study NCT01384591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo losartan
Description: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Study NCT01384591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo losartan
Description: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Study NCT01384591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo N-acetylcysteine
Description: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.
Study NCT01384591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo N-acetylcysteine
Description: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.
Study NCT01928147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-383
Study NCT01928147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01652092 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alemtuzumab 0.3 mg
Description: 0.3 mg/kg intravenously (IV) on days -12 through -10
Study NCT01652092 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: cyclophosphamide 50 mg/kg IV on days -9 through -6
Study NCT01652092 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2
Study NCT01652092 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stem Cell Transplantation
Description: Unrelated donor bone marrow will be collected in the usual manner using established parameters determined by the National Marrow Donor Program. A minimum of 3 x 10\^8 nucleated cells/kg recipient weight will be collected with a goal of ≥ 5 x 10\^8 nucleated cells/kg recipient weight.~Umbilical cord blood selection will be per the current University of Minnesota Cord Blood Unit Selection algorithm. One or two units may be used to obtain the minimum cell dose. One of the UCB units selected for transplantation must contain ≥ 3.5 x 10\^7 nucleated cells/kg recipient weight based on cell numbers at time of cryopreservation, and the total combined cell dose of both units must be > 5.0 x 10\^7 nucleated cells/kg.
Study NCT00463437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection, 1 dose.
Study NCT04640402 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: High-dose placebo (60-85 years) & Three dose regimen
Description: 60-85 years group, three doses of placebo(1.0ml) at the schedule of day 0, 14, 28.
Study NCT04225143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: urostim bilateral
Description: Treatment by bilateral neurostimulation of the tibial nerve
Study NCT04225143 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: urostim unilateral
Description: Treatment by unilateral neurostimulation of the tibial nerve
Study NCT04303637 — intervention group
Intervention type: BEHAVIORAL
Intervention: Phone use
Description: Objective and subjective reports of smartphone use (e.g., number of hours, number of pick-ups, how phones are used)
Study NCT01806792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate combine
Study NCT01806792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Study NCT01806792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo(for Risedronate)
Study NCT01806792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(for risedronate combine)
Study NCT01652092 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine phosphate 40 mg
Description: 40 mg/m\^2 IV on days -5 through -2 (for children \< 6 months and/or \< 10 kg weight dose at 1.33 mg/kg)
Study NCT01652092 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan
Description: 140 mg/m\^2 IV on day -3
Study NCT03469674 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy
Description: Internal radiation of the vaginal vault using a vaginal cylinder, 21 Gy in 3 out-patient sessions over 2 weeks
Study NCT01652092 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alemtuzumab 0.2 mg
Description: 0.2 mg/kg intravenously (IV) on days -14 through -10
Study NCT01652092 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6
Study NCT01554813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza split vaccine of 15 μg HA
Description: 60 subjects were assigned (20 infants, 20 children and 20 adults) to receive influenza vaccine (split virion), inactivated, 0.5ml, one dose regime
Study NCT01554813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza split vaccine of 15 μg HA
Description: 558 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
Study NCT01652092 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine phosphate 30 mg
Description: fludarabine 30 mg/m\^2 IV on days -8 through -4
Study NCT01652092 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MESNA
Description: administered as per the standard institutional protocol.
Study NCT01554813 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza split vaccine
Description: 280 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
Study NCT02158598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D chewable tablet supplementation
Study NCT02233985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: Salbutamol 100 micrograms / kg / dose administered 0.9% saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
Study NCT02233985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Sodium Chloride
Description: Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
Study NCT02403947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: After the sampling of bone-marrow and culture of MSCs by the French Blood Establishment (Midi-Pyrénées), patients will receive an IV injection of MSCs.
Study NCT02158598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D pill supplementation
Study NCT02995889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLT-PET
Study NCT04517539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF，Peginterferon alfa-b2，radiation
Description: Radiation:~If there are two measurable lesions totally, One lesion received radiotherapy for 30 Gy in 5 fractions and rested for one week; If there are three measurable lesions totally, two lesion received radiotherapy for 30 Gy in 5 fractions separately.~drug: Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy. Peginterferon alfa-b2 90 ug in d8 in each cycle.~And the 1 month after the end of all radiotherapy courses, 4 weeks as a course of treatment, once per course of treatment, each dose is 90μg until desease progress.
Study NCT02403947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Suspension media
Description: injection suspension media
Study NCT00708669 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS stent
Description: Compared two kinds of stents:TAXUS stent, approved for commercialization in Japan(March 30th, 2007)
Study NCT00708669 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher stent
Description: CYPHER stent, approved for commercialization in Japan(March 25, 2004)
Study NCT01356810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Intervention
Description: The environmental intervention consisted of daily reorientation, avoidance of sensorial deprivation, longer visiting hours, the availability of a clock, a calendar and the presence of familiar objects in the room.
Study NCT01356810 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Delirium management by the attending physician's preferences.
Study NCT02219204 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Study NCT00781794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSA-789 at 2 different doses
Study NCT00463437 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar
Description: Intramuscular injection, 1 dose.
Study NCT02219204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Herbal treatment
Study NCT01479530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily; tablet; orally; 16 weeks
Study NCT01479530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilect®
Description: 1 mg daily; tablet; orally; 16 weeks
Study NCT00463437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 1 dose. In Germany and Poland.
Study NCT03061019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Myofunctional Therapy with exercices
Description: Oral-Motor training of oral muscles (tongue, lips) associated with nasal hygiene with daily repetition of exercices and parental support.
Study NCT00781794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NSA-789 at 2 different doses
Study NCT02479633 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Coronally advanced flap with connective tissue graft
Description: Two oblique, divergent releasing incisions extending beyond the mucogingival junction were performed. An intra-sulcular incision was performed at the buccal aspect of the involved tooth. Subsequently, a partial-thickness flap was raised beyond the MGJ. The papilla adjacent to the involved tooth were then de-epithelialized.~The CTG was harvested using a single incision approach from the palate. The graft was positioned on the instrumented root surface immediately apical of the CEJ and then stabilized using a sling compressive crossing suture. The flap was coronally displaced 1-2 mm above the CEJ. A sling suture was placed to stabilize the flap in a coronal position, followed by interrupted sutures on the releasing incisions with an apico-coronal direction.
Study NCT00463437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix IPV Hib
Description: Intramuscular injection, 1 dose. In Spain.
Study NCT03061019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Myofunctional Therapy with soft oral appliance
Description: Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
Study NCT02271802 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium butyrate
Description: Patients recieved an enema containing butyrate or a placebo during upper abdominal surgery.
Study NCT02271802 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Study NCT00514527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oritavancin
Description: Oritavancin as a single, infrequent or daily dose.
Study NCT04071886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Training
Description: Mindfulness-Based Training comprises of mindful walking, body scanning and raisin meditation exercise. Participants will receive a guided session of mindfulness meditation, and will be asked to finish at least 30 minutes of Mindfulness-Based Training every day as homework as well as keep a diary describing their experiences and reflections. An expert in mindfulness practice will offer feedback and answer any questions online.
Study NCT04071886 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Training
Description: Participants will listen to a 15-minute Relaxation Training tape twice a day.
Study NCT01995435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine refraction
Study NCT04024163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: Drug: Benznidazole Tablets 100 mg (functionally scored) or Tablets 12.5 mg
Study NCT03769896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nabilone 0.25 mg
Description: capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis
Study NCT01995435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional refraction
Study NCT03185507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoHelmet
Description: Cryotherapy was administered using the Catalyst CryoHelmet™ (All-Star Sporting Goods®, Shirley, Massachusetts, USA). The CyroHelmet is a flexible helmet equipped with gel ice packs meant to cool the head and neck.
Study NCT02830633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LNTME
Description: Patients in this group received laparoscopy-assisted nerve-preserved TME for treatment of rectal cancer
Study NCT02830633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OTME
Description: Patients in this group received traditional open TME for treatment of rectal cancer
Study NCT02710747 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2C9;VKORC1
Study NCT03469674 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal brachytherapy
Description: Internal radiation of the vaginal vault using a vaginal cylinder, 21 Gy in 3 out-patient sessions over 2 weeks
Study NCT03469674 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: External beam pelvic radiotherapy on a linear accelerator, 48.6 Gy in 27 out-patients sessions over 5.5 weeks
Study NCT03469674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: No radiation therapy, but active follow-up and quality of life questionnaires as in the groups who have adjuvant treatment
Study NCT00463437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix penta
Description: Intramuscular injection, 1 dose. In Germany and Poland.
Study NCT00463437 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix penta
Description: Intramuscular injection, 1 dose. In Germany and Poland.
Study NCT00463437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix IPV
Description: Intramuscular injection, 1 dose. In Spain.
Study NCT00463437 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix IPV
Description: Intramuscular injection, 1 dose. In Spain.
Study NCT00463437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningitec
Description: Intramuscular injection, 1 dose.
Study NCT00463437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeisVac-C
Description: Intramuscular injection, 1 dose.
Study NCT00463437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menitorix
Description: Intramuscular injection, 1 dose.
Study NCT00463437 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menitorix
Description: Intramuscular injection, 1 dose.
Study NCT02715648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine
Study NCT02256358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: preoperatively injected intravenous 0.1 mg/kg midazolam
Study NCT02256358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Preoperatively injected intravenous 1mg/kg ketamine